格隆汇1月9日丨康龙化成(300759.SZ)公布，为进一步借助专业投资机构在行业内的投资筛选与研判能 力，提升公司的投资能力，同时促进医药行业的高质量发展，公司拟以自有资金对宁波甬康追加投资 5,000万元人民币。本次追加投资完成后，公司对宁波甬康认缴出资额共计15,000万元人民币，占基金认 缴总额的87.1343%。2026年1月9日，公司签署了《关于宁波甬康股权投资合伙企业（有限合伙）之有 限合伙协议》。 ...

证券代码：600196 股票简称：复星医药 编号：临2026-001 上海复星医药（集团）股份有限公司 关于参与认购之投资基金完成私募投资基金备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 基金名称：华润（成都）医药产业股权投资基金合伙企业（有限合伙） 管理人名称：深圳市华润资本股权投资有限公司 托管人名称：招商银行股份有限公司 备案编码：SBLL28 特此公告。 上海复星医药（集团）股份有限公司 一、概况 2025年10月28日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海复星医药 产业发展有限公司与其他11方投资人签订《华润（成都）医药产业股权投资基金合伙企业（有限合伙） 有限合伙协议》，以共同出资设立华润（成都）医药产业股权投资基金合伙企业（有限合伙）。 以上详情请见本公司2025年10月29日于《中国证券报》《上海证券报》《证券时报》和上海证券交易所 网站（https://www.sse.com.cn）发布的相关公告。 二、进展情况 近日，本公司收到通知，该基金已于中国证券投资基金业 ...

Core Viewpoint - The company, Ruizhi Pharmaceutical, announced a strategic partnership with professional investment institutions to enhance its capabilities in the innovative drug industry through a new investment fund [2] Group 1: Investment Details - The company’s wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., will collaborate with Shenzhen Investment Control Donghai Investment Co., Ltd. and other partners to establish a new investment fund named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership [2] - The total committed capital for the partnership is set at RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [2] - The partnership has completed the necessary registration and obtained the Private Investment Fund Registration Certificate in compliance with relevant Chinese regulations [2]

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference will be held on October 26-27, 2025, in Nanjing, focusing on global pharmaceutical frontiers and capital trends, gathering top minds in the pharmaceutical innovation and investment fields [1][2]. Conference Information - The conference will take place at Fengda International Hotel, Nanjing, and will cover multiple thematic forums including innovative drug research and development, clinical research, cell and gene therapy, investment mergers and acquisitions, capital markets, and commercial insurance policies [2]. - The agenda includes various sub-forums such as cell and gene therapy, weight loss innovation, clinical data, anti-tumor new drugs, and international roadshows, ensuring comprehensive coverage of the pharmaceutical industry [3][4]. Key Topics - The conference will address core challenges and development trends in the pharmaceutical industry, emphasizing internationalization, investment financing, and regulatory policies, with a focus on the synergy between basic medical insurance and commercial health insurance [5]. - Discussions will include the strategies of Chinese innovative pharmaceutical companies in global markets, particularly in terms of licensing, mergers, and new investment trends [5][6]. Expert Participation - The conference will feature senior experts, clinical specialists, industry leaders, and frontline investors who will share insights on breakthrough technologies, practical experiences in investment mergers, and policy interpretations [4][6]. - Notable speakers include leaders from prestigious institutions and companies, contributing to discussions on the construction of innovative ecosystems and cross-sector collaboration [4][6]. Forum Structure - The conference will be structured around multi-dimensional forums designed to promote deep dialogue and knowledge sharing across clinical, industrial, capital, and policy fields, with three core discussion directions: global strategic layout, capital collaborative innovation, and market trend outlook [6].

Group 1 - The company announced the establishment of a new partnership for investment in the pharmaceutical industry, involving its wholly-owned subsidiary Beihai Ruizhi Venture Capital Co., Ltd. [1] - The total committed capital for the new partnership, Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership), is set at 200 million yuan, with Beihai Ruizhi contributing 58 million yuan, representing 29% of the total commitment [1]

Core Viewpoint - East China Pharmaceutical (000963.SZ) aims to enhance its industrial investment ecosystem and expand its industry chain layout by establishing a partnership with Shanghai Fuguang Private Fund Management Co., Ltd. and other investors to create a specialized pharmaceutical industry investment fund totaling RMB 2 billion [1] Group 1: Investment Details - The total committed capital for the specialized pharmaceutical industry investment fund is RMB 2 billion, with East China Pharmaceutical contributing RMB 980 million, representing a 49% stake [1] - The fund will focus on investment areas including innovative drugs, medical aesthetics, health and wellness, animal health, and sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]

Group 1 - The company, Huadong Medicine (000963.SZ), announced its participation as a limited partner in a new investment fund, "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)" [1] - The total committed capital for the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [1] - The investment focus of the fund includes innovative pharmaceuticals, medical aesthetics, health and wellness, animal health, and other sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]

Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

Core Viewpoint - The agreement outlines the terms for the issuance of shares by Ruizhi Medical Technology Co., Ltd. to Jiangmen Ruilian Medical Investment Co., Ltd. for the year 2024, including share transfer and ownership changes [1][2][3]. Group 1: Share Issuance Agreement - The agreement was signed on April 1, 2025, between Ruizhi Medical Technology Co., Ltd. and Jiangmen Ruilian Medical Investment Co., Ltd. [1] - The total registered capital of Ruizhi Medical is RMB 497.96 million, with a total share count of 100% held by MEDICAL LIMITED [1]. - WOO SWEE LIAN, the actual controller, currently holds 5.11% of the shares, with an additional 4.56% held by MEGA STAR [1]. Group 2: Share Transfer and Ownership Changes - Following a court ruling, WOO SWEE LIAN and his associates will hold 15.70% of the shares after the forced transfer of 30,033,098 shares from another shareholder [2]. - After the completion of a share transfer agreement, WOO SWEE LIAN and his associates will collectively own 21.18% of the shares, maintaining his position as the controlling shareholder [3]. Group 3: Subscription Details - The agreement allows for the issuance of up to 60,019,704 shares, representing 30% of the total share capital prior to the issuance, at a price of RMB 5.27 per share [4][5]. - The subscription amount will be determined by the number of shares multiplied by the issuance price, with funds sourced legally by the subscriber [5]. - The shares subscribed will have a lock-up period of 18 months post-issuance [5]. Group 4: Legal and Compliance - The agreement is subject to approval from the board of directors and shareholders, as well as regulatory approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [7]. - Any modifications to the agreement must be documented in writing and comply with legal procedures [7][8].